Phase III trial evaluating the role of adjuvant pegylated liposomal doxorubicin (PLD, Caelyx, Doxil) for women (age 66 years or older) with endocrine nonresponsive breast cancer who are not suitable for being offered a 'standard chemotherapy regimen'.

Trial Profile

Phase III trial evaluating the role of adjuvant pegylated liposomal doxorubicin (PLD, Caelyx, Doxil) for women (age 66 years or older) with endocrine nonresponsive breast cancer who are not suitable for being offered a 'standard chemotherapy regimen'.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Cyclophosphamide; Doxorubicin liposomal; Methotrexate
  • Indications Early breast cancer; Menopause
  • Focus Therapeutic Use
  • Acronyms CASA
  • Most Recent Events

    • 20 Jul 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
    • 20 Jul 2012 Actual end date (1 Dec 2011) added as reported by ClinicalTrials.gov.
    • 30 Jun 2012 Additional trial locations (France, Slovenia) added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top